Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, van Tinteren H, Praag JO, et al. Quality of life. , & Reijneveld, S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. SLOTMAN B, SENAN S. Experiences of case managers in providing. Kim, & Blakeney, ). Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiother. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kumar,. . SLOTMAN BJ, VOS PH. Slotman BJ, Senan S. Oncol. (). Planning of radiotherapy capacity and productivity. J Thorac Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiobiological.